Taking the above into consideration, we hypothesized that the inhibition of HDAC6 could improve the anti-tumor effect of anti-PD-1 blockade by decreasing the expression of molecules involved in immunosuppressive pathways (i.e. PD-L1) and enhancing the antigen presentation machinery. This evidence concerns the gene CD274 and neoplasm.